Kevin D Burroughs
Overview
Explore the profile of Kevin D Burroughs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gavrin L, Mahaney P, Jenkins D, Nogle L, Mugford C, Huselton C, et al.
ACS Med Chem Lett
. 2014 Jun;
1(3):91-5.
PMID: 24900182
The potency and selectivity of a series of 1-{(1S)-2-[amino]-1-[3-(trifluoromethoxy)phenyl]ethyl}cyclohexanol analogues are described. These compounds were prepared to improve in vitro metabolic stability and achieve brain penetration. Compound 13 (WAY-260022, NRI-022)...
2.
Poirier J, Reddy P, Idamakanti N, Li S, Stump K, Burroughs K, et al.
J Gen Virol
. 2012 Sep;
93(Pt 12):2606-2613.
PMID: 22971818
Seneca Valley virus (SVV-001) is an oncolytic picornavirus with selective tropism for a subset of human cancers with neuroendocrine differentiation. To characterize further the specificity of SVV-001 and its patterns...
3.
Willcocks M, Locker N, Gomwalk Z, Royall E, Bakhshesh M, Belsham G, et al.
J Virol
. 2011 Feb;
85(9):4452-61.
PMID: 21325406
The RNA genome of Seneca Valley virus (SVV), a recently identified picornavirus, contains an internal ribosome entry site (IRES) element which has structural and functional similarity to that from classical...
4.
Rudin C, Poirier J, Senzer N, Stephenson Jr J, Loesch D, Burroughs K, et al.
Clin Cancer Res
. 2011 Feb;
17(4):888-95.
PMID: 21304001
Purpose: Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a...
5.
Mahaney P, Kim C, Coghlan R, Cohn S, Heffernan G, Huselton C, et al.
Bioorg Med Chem Lett
. 2009 Aug;
19(19):5807-10.
PMID: 19713106
The SAR of a series of 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols as monoamine reuptake inhibitors, with a goal to improve both potency toward inhibiting the norepinephrine transporter and selectivity over the serotonin transporter, is...
6.
Mahaney P, Gavrin L, Trybulski E, Stack G, Vu T, Cohn S, et al.
J Med Chem
. 2008 Jun;
51(13):4038-49.
PMID: 18557608
Further exploration of the cycloalkanol ethylamine scaffold, of which venlafaxine ( 1) is a member, was undertaken to develop novel and selective norepinephrine reuptake inhibitors (NRIs) for evaluation in a...
7.
Reddy P, Burroughs K, Hales L, Ganesh S, Jones B, Idamakanti N, et al.
J Natl Cancer Inst
. 2007 Nov;
99(21):1623-33.
PMID: 17971529
Background: Numerous clinical trials have demonstrated that oncolytic viruses can elicit antitumor responses when they are administered directly into localized cancers. However, the treatment of metastatic disease with oncolytic viruses...
8.
Burroughs K, Kayda D, Sakhuja K, Hudson Y, Jakubczak J, Bristol J, et al.
Cancer Gene Ther
. 2004 Jan;
11(2):92-102.
PMID: 14730331
Oncolytic adenoviral vectors selectively replicate in and lyse human tumor cells, providing a promising means for targeted tumor destruction. However, oncolytic vectors have limited capacity for incorporation of additional genetic...
9.
Burroughs K, Oh J, Barrett J, DiAugustine R
Mol Cancer Res
. 2003 Mar;
1(4):312-22.
PMID: 12612059
Due to the importance of vascular endothelial growth factor (VEGF) in the neovascularization of solid tumors, a clear understanding of how VEGF is regulated in normal and tumor cells is...